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1. Introduction  
The 7-valent pneumococcal conjugate vaccine (PCV-7) was firstly approved in 
the USA in 2000 for the prevention of diseases caused by Streptococcus pneumoniae 
(pneumococcus) among infants and young children.  In 2007, WHO recommended the 
vaccine to be incorporated into national childhood immunisation programmes in every 
country [1].  In 2009, two pneumococcal vaccines with extended serotype coverage, 
10-valent (PCV-10) and 13-valent (PCV-13), were introduced, and since then, they 
have been gradually replacing PCV-7 [2].  The PCV-10 conjugates to non-typable 
Haemophilus influenza carrier protein, while PCV-13 conjugates to the same carrier 
protein (CRM197) as PCV-7.  In order to support the adoption of PCV-10 or PCV-13, 
cost-effectiveness studies have been performed in various countries.  In general, 
results of these studies have demonstrated that the use of PCV-10 or PCV-13 is 
cost-effective or cost saving compared to PCV-7 vaccination programme in prevention 
of the disease caused by Streptococcus pneumoniae (S. pneumoniae) [3-6]. 
In Japan, PCV-7 was approved on October 26, 2009.  The government 
disbursed a budget to encourage municipalities in launching a public 3+1 dose 
vaccination programme (3 primary doses and 1 booster dose) on November 26, 2010, 
which will continue until March 31, 2013.  Therefore, currently all municipalities 
give subsidies to PCV-7 vaccinees.  The attainable vaccination rate for Japanese 
infants is considered to be about 60%, according to the ‘‘Provisional Special Fund for 
the Urgent Promotion of Vaccination against Such Diseases as Cervical Cancer’’  by 
the government in 2011.  A study group of ten health institutions and affiliated 
paediatricians have reported that there was a decrease in invasive pneumococcal 
diseases (from 333 cases in 2010 to 113 cases in 2011) after the introduction of PCV -7 
[7].  As to PCV-10 and PCV-13, both are not yet available in Japan, while the latter is 
now under the process of approval and experts have expressed their expectations [8].  
The possible availability of PCV-13 raises the need to evaluate effective ways in 
protecting the birth cohort from pneumococcal -related diseases in Japan. 
It is said that there are five hurdles to overcome in the diffusion process of new 
health intervention: quality, safety, efficacy, cost -effectiveness and affordability [9].  
In regards to the cost-effectiveness and affordability of PCV-7 vaccination programme, 
our recently published economic evaluation of  using PCV-7 to the birth cohort in Japan 
suggests that if we adopt WHO's criterion that an intervention is 'cost -effective' if 
ICER (in QALY) is between 1 and 3 times of GDP per capita, then PCV-7 vaccination 
programme would be an efficient use of finite resources in healthcare from the societal 
perspective, regardless of the co-payment level [10].  Furthermore, the study shows 
that if full subsidy is provided for the vaccination programme, the level of budget 
impact is less than ¥11,000,000 (US$137,500; US$1 = ¥80, based on the average 
exchange rate of 2012) for a municipality with 1,000 birth cohort in the 1st year, and 
2nd to 5th year birth cohort proportional to the birth cohort population of estimated 
future population. 
This study aims to investigate the cost-effectiveness of replacing the current 3+1 
dose schedule of PCV-7 vaccination programme with 3+1 dose schedule of PCV-13 
vaccination programme in Japan, foreseeing the possible replacement after the approval 
of PCV-13.  The results should deepen our understanding about the implications of 
preventing pneumococcus-caused diseases among infants and young children to  
healthcare financing and inform policy makers of Japan as well as in other developed 
countries.  Since PCV-10 is not even under the process of approval, it is not considered 
as an alternative in this study, however, if in such case, we may evaluate with 
appropriate comparator, either PCV-7, PCV-13, other PCV products [11], or all. 
2. Method 
We conduct a cost-effectiveness analysis with Markov modelling from the 
societal perspective.  The Markov model is from our previous study [10], while 
epidemiological data and resource use are updated.  Japanese data sources are reviewed 
together with international literature to parameterise the model. 
2.1. Programmes and Markov model 
We define two vaccination programmes:  current PCV-7 programme and the 
possible replacement, i.e., PCV-13 programme, with the same vaccination schedule 
(3+1).  We assume that vaccination is fully subsidised for the uptake of 4 doses of 
either PCV-7 or PCV-13.  The average vaccine uptake rate for both vaccination 
programmes is set as 76.1%, which is the rate of DPT vaccination programme in 2010 
[12].  This rate is adopted for two reasons:  first, it has been a mere two years since 
the introduction of PCV-7 in Japan, and no adequate data is yet available to estimate 
its uptake rate; secondly, the vaccination schedule of DPT is similar to that of PCV-7 
and PCV-13.  We also assume that among the vaccinees of first 3 doses, 13.8% will 
uptake PCV-7/PCV-13 alone, while 23.1% will uptake simultaneously with Hib 
vaccine, and 63.1% will uptake simultaneously with one other vaccine listed in the 
national immunisation schedule [13].  In regards to the 4th dose, 40% will uptake 
PCV-7/PCV-13 alone, and 60% will uptake simultaneously with one other listed 
vaccine [13]. 
We then consider about the municipality’s decision in launching  a 5-year 
programme, which is assumed for reconsideration or redesigning of the programme, as 
it is often employed in organising public health programmes in Japan [14].  The birth 
cohorts of five years used in the model are from Population estimates of Japan [15].  
Incremental cost-effectiveness ratios (ICERs) of PCV-13 programme to PCV-7 
programme are calculated to determine the efficiency of the resource use . 
The disease model of the health effects of pneumococcal vaccination includes 
the possibility of subsequent pneumococcal disease , such as:  bacteraemia (including 
sepsis), meningitis, all-cause hospitalised pneumonia, acute otitis media (AOM, 
including simple and complex), sequelae after meningitis, and death from or other than 
the related diseases in the model  (Fig. 1).  A Markov cycle for each stage is set at 1 
year.  The time frame is 5 years after the entering of a birth cohort because the 
diseases caused by S. pneumoniae decrease significantly among children aged 5 years 
and over [16].  Life expectancy of survived patient with or without neurological 
sequelae is assumed as 53.9 years or to have a life expectancy of Japanese population, 
respectively [10].  Adverse effects associated with vaccination are not considered 
because those of PCV-13 are similar to those of PCV-7 [17-19]. 
2.2.Outcomes estimation 
Outcomes in terms of years of life saved (YOLS) and quality adjusted life year 
(QALY) are estimated by assigning transition probabilities and utility weights from the 
literature to the Markov model.  
2.3. Annual incidence rates and case fatality rates 
Annual incidence rates of meningitis and of bacteraemia among children 
younger than 5 years old without vaccination are derived from a three-year (2007-2009) 
nationwide survey by Kamiya et al. [20]; of AOM are computed by the AOM episodes 
by child [21], multiplied by the “proportion of clinically diagnosed AOM episodes due 
to pneumococcus (34.1%)” [22]; of hospitalised community acquired pneumonia (CAP) 
are from a retrospective study of 18 hospitals with paediatric wards in Chiba city, Japan 
[23].  Proportions of meningitis that resulted in hearing impairment or neurological 
sequelae are from Kamiya et al. [20] and Iwata et al. [24].  Case fatality rates of 
meningitis and of bacteraemia are also from Kamiya et al.  [20]; of hospitalised 
pneumonia are estimated from Patient survey [25] and Vital statistics [26].  Deaths 
from causes other than the above diseases are also from the Vital statistics [26].  All 
these rates are shown in Table 1.  
2.4. Vaccine effectiveness 
2.4.1. Direct effect 
The vaccine effectiveness (VEs) of PCV-7 against vaccine-serotype- IPD 
(including bacteraemia and meningitis), vaccine-serotype- AOM, and hosiptalised 
radiograph-comfirmed pneumonia among children under 2 years old are 80%, 54%, and 
27%, respectively, based on the systematic review reported by the Cochrane 
Collaboration [27,28].  The VEs of PCV-13 are not available at the time of this study.  
Based on the immunogenicity data, we assume PCV-13 is as immunogenic as PCV-7 
for common serotypes and has comparable levels of antibody for serotypes unique to 
PCV-13 [2, 18, 19].  Proportion of IDP episodes due to PCV-7/PCV-13 serotype is 
assumed as 68.5%/80.9% [7]; of hospitalised community acquired pneumonia (CAP) 
episodes, 66.7%/81.0% [23]; of AOM episodes, 68,2%/86.0%, for 0 to <3 years old, 
and 48,5%/77.9% fir 3 to <5 years old [29].   The VEs against IPD and AOM are of 
specific vaccine serotypes only, therefore, they are multiplied by the proportion of 
relevant disease episodes due to PCV-7/PCV-13 serotypes to adjust to our disease 
model, while the VEs against hospitalised pneumonia are not of specific vaccine 
serotypes, and therefore there is no need to adjust.  For those aged over 2 and under 5 
years, the VEs against IPD and hospitalised pneumonia are assumed to decline by 3% 
annually for both PCV-7 and PCV-13 [30].    All these data are shown in Table 1. 
No efficacy data against otitis media were available for serotypes 1, 3, 5, 6A, 
7F, and 19A from the package insert of Prevenar 13® (brand name of PCV-13) sold in 
the US [31].  Therefore, we set two base-cases for analyses:  “Base-case A”, which 
assumes that the prevention of AOM by PCV-13 is limited to the seven serotypes of 
PCV-7 only; and “Base-case B”, which assumes that the prevention of AOM by PCV-13 
is straightforwardly extended to cover non-PCV-7 serotypes. 
2.4.2. Indirect effects 
We do not consider the net indirect vaccine effect (herd protection minus 
serotype replacement effect) in our base-case analysis, but conduct four scenario 
analyses by assuming different net  indirect effects among children aged under 5 years 
old as observed in European countries and the US.  Assumptions made for each 
scenario and two base-cases are shown in Table 2.  The net indirect effect in 
non-vaccinated children older than 5 years old is not considered in the scenario 
analyses because of the discrepancies among reports from previous studies [ 32].  In 
the US, indirect effects was observed among adults after the nationwide 
implementation of PCV-7 in 2000, while in European countres, such as Spain, France, 
and the UK, no overall reduction of IPD incidences were observed among adults even 
after three years of introduction in routine vaccination [32].  Rozenbaum indicates 
that possible factors responsible for these differences may inclu de the 
vaccine-serotype coverage, and/or implemented vaccination schedules,  and/or 
antibiotic resistance rates, and/or pneumococcal disease incidences prior to 
vaccination. 
2.5. Costing 
From the societal perspective, costing should cover the opportunity costs borne 
by various economic entities in the society [33].  In the context of this study, the 
amount of direct payments costs borne by municipal authorities, vaccinees, patients and 
social insurers are considered, while indirect costs of vaccination programme are not 
included, because it is assumed that the programme is  built within the public health 
services infrastructure.  Therefore, costs of vaccination, treatment costs of  
pneumococcal-related diseases and costs associated to care-giver’s lost productivity, 
such as accompanying a child for vaccination, for medical treatment, or to take  care of a 
child with sequelae, are counted.  Productivity loss due to mortality or morbidity is not 
included, as including this into cost-effectiveness analysis may be argued as double 
counting while survived cases are incorporated in the utility weights and disease  
duration in calculating QALYs [33]. 
2.5.1. Direct medical costs  
The vaccination cost per a shot of PCV-7 is assumed at ¥10,000 (US$125) [10]; 
per a shot of PCV-13 is assumed at 1.3 times that of PCV-7 based on the report from 
“The Pharma Letter”  [34].  Treatment costs per episode of survived/fatal bacteraemia , 
survived/fatal meningitis, and long-term treatment costs for an individual with hearing 
impairment or neurological sequelae are according to Iwata et al. [24].  Treatment 
costs per episode of pneumonia caused by S. pneumoniae are according to Ishiwada et al. 
[35].  Treatment costs per episode of AOM are the weighted average of simple and 
complex cases reported by Yamanaka et al. [21].  The proportions of complex cases 
are:  37%, 49%, 25%, 19%, and 14%, for children aged 0 to <1, 1 to <2, 2 to <3, 3 to <4, 
and 4 to <5, respectively [21].  All these costs are shown in Table 3. 
2.5.2. Productivity loss by care-giver 
Under the context of this study, productivity loss per disease episode or per shot 
is valued as a product of care-giver’s absent working hours  from paid employment (8 
working hours/day) and an average hourly wage, ¥1,328 (US$17), of Japanese women 
labourers [36].  Productivity loss of a care-giver to accompany a child for one uptake 
of vaccine is assumed as a half of a day (4h) when uptaking PCV-7 or PCV-13 alone, 
1/2×4h when uptaking simultaneously with Hib vaccine.  1/2×4h is assumed because 
Hib vaccination programme was introduced on the same day as PCV-7 vaccination 
programme in Japan, and therefore, 4h of productivity loss should be shared equally in 
simultaneous uptake of PCV-7/PCV-13 and Hib vaccine.  And 0h, when uptaking 
simultaneously with one other listed vaccine, because it can be assumed that no 
incremental productivity loss occurs to uptake PCV-7/PCV13 in particular.  As to the 
productivity loss per disease episode, the frequency of outpatient visits and the number 
of hospitalisation days of a meningitis episode  are from Yamanaka et al. [21]; of a 
pneumonia episode are from Ishiwada [35].  We assume 4 absent working hours for one 
outpatient visit and 8 absent working hours for one hospitalised day.  The average 
absent working hours of an AOM episode are the weighted average of simple and 
complex AOM derived from Yamanaka et al. [21].  We assume that the absent working 
hours of a care-giver to take care of one child with hearing impairment or neurological 
sequelae is 8 hours per day until the child is admitted to  special support education 
system, which is at age 6 in Japan.  
2.6. Discounting 
Costs and outcomes were discounted at a rate of 3% [33]. 
2.7. Scenario analyses, sensitivity analyses, and probabilistic analyses 
In order to assess the impact of herd effects on outcomes of PCV -7/PCV-13 
vaccination, scenario analyses, which assume four different net indirect effects in 
non-vaccinated children aged under 5 years old (Table 2), are performed:  Scenario-1 
limits the herd effect to IPD only; Scenario-2 extends the effect to IPD and hospitalised 
pneumonia; Scenario-3 extends the effect to IPD and AOM; and Scenario-4 assumes the 
effect to all the diseases, i.e., IPD, hospitalised pneumonia and AOM.  We assume the 
protection resulted from herd effects would be as effective as direct effects of 
vaccination, based on the report from the US [37].  One-way sensitivity analyses are 
performed on cost of one shot of PCV-13 as well as on the VEs of PCV-7 and PCV-13, 
which several studies have reported to have a significant impact on the results.  For a 
cost of one shot of PCV-13, lower and upper values are set at ¥10,000 (US$125, equal to 
the current cost of PCV-7) and ¥20,000 (US$250, double the current cost of PCV-7), 
respectively.  For the VEs of PCV-7, the lower value is changed by -20%, while the 
upper value is set equal to the VEs of PCV-13.  On the other hand, for the VEs of 
PCV-13, the upper value is changed by +20%, and the lower value is set equal to the 
VEs of PVC-7.  Sensitivity analyses on epidemiological data, life expectancy,  utility 
weights and treatment costs of disease episodes are omitted because these are assumed 
as similar in both PCV vaccination programmes.  
We also conduct a thousand times Monte Carlo simulation, i.e., probabilistic 
analyses, for which VEs are assumed to have an equilateral triangle distribution 
corresponding to the range tested in one way sensitivity analyses.  Other variables are 
fixed at their base-case values. 
3. Results 
3.1. Avoided cases 
The estimated disease cases avoided by PCV-7/PCV-13 vaccination programme 
compared with no programme for 100,000 birth cohort in the five year period are as 
follow:  8.2/9.7 cases of meningitis, 49.4/58.4 cases of bacteraemia, 1739.4/ 2112.9 
cases of hospitalised pneumonia, 66,188/66,188 (Base-case A) or 72,728 (Base-case B) 
of AOM, and 1.86/2.26 cases of death due to either meningitis, bacteraemia or 
pneumonia.  If PCV-13 replaces PCV-7, the estimated incremental number of avoided 
cases will be:  1.49 of meningitis, 8.94 of bacteraemia, 373.5 of hospitalised 
pneumonia, none or 6540.2 of AOM in Base-case A or Base-case B, respectively, and 
0.40 cases of death due to either meningitis, bacteraemia or pneumonia.  The reduced 
disease cases resulting from replacing PCV-7 with PCV-13 would be 18.1%, 21.5%, and 
9.9%, for IPD, hospitalised pneumonia, and AOM, respectively.  
3.2. Cost, effectiveness, and cost-effectiveness 
Given the purpose of this study, the description should focus on the comparison 
between PCV-13 programme and PCV-7 programme.  The results of the comparison 
between PCV-7/PCV-13 against no-programme are shown in Table 4 as reference.  
Table 4 shows the results of base-case analyses.  When comparing PCV-13 
programme with PCV-7 programme, estimated average incremental effects per child are 
0.0002QALY/0.0001YOLS for Base-case A, and 0.0011QALY/0.0001YOLS for 
Base-case B.  In terms of QALY gained, IPD contributed 7.1%, hospitalised pneumonia 
contributed 11.9%, and AOM contributed 81.0% to the figures (in Base-case B). 
PCV-13 programme reduces both disease treatment costs and care-giver’s 
productivity loss due to disease treatment.  However, when the care-giver’s 
productivity loss is not included, the reduced disease treatment costs alone do not offset 
the vaccination cost, which means that the vaccination programme turn s out to be ‘gain 
more but cost more’.   Estimated ICERs are ¥37,722,901 (US$471,536) per QALY 
gained or ¥5,4261,241 (US$678,266) per YOLS gained for Base-case A; ¥343,830 
(US$4,298) per QALY gained or ¥2,606,959 (US$32,587) per YOLS gained for 
Base-case B.  When the care-giver’s productivity loss is included, the ICERs are 
¥35,584,455 (US$444,806) per QALY gain or ¥51,185,265 (US$639,816) per YOLS 
gain for base-case A.  While for Base-case B, the sum of reduced disease treatment 
costs and reduced caregiver’s productivity loss outweigh s the vaccination cost.  It can 
be concluded that PCV-13 programme not only gains more QALY/YOLS but also saves 
money compared to PCV-7 programme. 
3.3. Uncertainty analyses 
Table 5 shows the results of eight scenario analyses.  ICER decreases as 
expected from indirect effect.  In Base-case A, it decreases from ¥37,722,901 
(US$471,536) to ¥33,661,992 (US$420,775) in Scenario-1; to ¥27,824,591 
(US$347,807) in Scenario-2; to ¥31,387,702 (US$392,346) in Scenario-3; and to 
¥25,682,885 (US$321,036) in Scenario-4; per QALY, when care-giver’s productivity 
loss is not included.  In Base-case B, it decreases from ¥343,830,(US$4,298) to 
¥308,676 (US$3,858) in Scenario-1; to ¥115,860 (US$1,448) in Scenario-2; cost less 
and gain more in both Scenario-3 and Scenario-4; per QALY, when caregiver’s 
productivity loss is not included.  It consistently costs less and gains more in all eight 
scenarios when caregiver’s productivity loss is included. 
Fig. 2(a) and 2(b) show how the ICER of PCV-13 programme varies with 
changing costs per shot compared to PCV-7 programme.  PCV-13 dominates (costs 
less and gains more) PCV-7 at cost per shot equal to or lower than that of PCV-7, i.e., 
¥10,000 (US$125) in Base-case A regardless of care-giver’s productivity loss, and 
regardless of measuring QALY or YOLS; While in Base-case B, ¥12,000 (US$150) or 
¥16,000 (US$200), when care-giver’s productivity loss is included or not included, 
respectively. 
Fig.3 shows the results of one-way sensitivity analyses performed on VEs which 
decrease or increase the ICER more than ¥500,000 (US$6,250) per QALY.  The top 
10 variables are all related to VE against AOM.  Among the variables, the VE of 
PCV-13 against AOM (1 to 2 years old) shows the largest impact on the result.  The 
upper/lower value of this variable decrease/increase the ICER by ¥894,798 
(US$11,185)/¥887,925 (US$11,099) per QALY, which is -260%/+258% of the ICER of 
the base-case. 
Fig. 4 presents four cost-effectiveness acceptability curves (CEACs)  estimated by 
the probabilistic sensitivity analyses:  For Base-case A, when productivity loss is 
included/not included, the probability of ICER to be less than ¥5,000,000 (US$62,500) 
per QALY is 3.8%/0.1%, respectively.  For Base-case B, when productivity loss is 
included/not included, the probability that PCV-13 programme dominates PCV-7 
programme is 99.0%/42.5%, and the probability of ICER to be less than ¥5,000,000 
(US$62,500) per QALY is 99.9%/95.0%. 
 
4. Discussion 
We estimate the cost-effectiveness of replacing the current PCV-7 vaccination 
programme with PCV-13 vaccination programme, and the effectiveness of PCV-13 is 
calculated based on the effects of PCV-7 and the serotype coverage of PCV-13 
compared to PCV-7, as done in other studies [4- 6]. 
Our base-case analyses, which sets the cost of PCV-13 per shot at 1.3 times that 
of PCV-7 (¥13,000/US$163), shows that in Base-case A (assumed PCV-13 has no 
additional protection against AOM compared to PCV-7), replacing PCV-7 with PCV-13 
will cost an additional ¥37,722,901 (US$471,536) or ¥35,584,455 (US$444,850) per 
additional QALY when the caregiver’s productivity loss is not included or is included, 
respectively.  While in Base-case B (assumed PCV-13 has additional protection against 
AOM compared to PCV-7), ¥343830 (US$4,298) per additional QALY or more QALY is 
gained by saving money without or with caregiver’s productivity loss, respectively.  
Sensitivity analyses on cost of one shot of PCV-13 show that in Base-case A, if 
the cost of one shot of PCV-13 is equal to that of PCV-7, i.e., ¥10,000 (US$125), 
replacing PCV-7 with PCV-13 will save money and gain more QALY or YOLS 
regardless of caregiver’s productivity loss.  At cost equal to or less than 11,000 
(US$138), ICER will be lower than ¥10 million (US$125,000) per QALY regardless of 
caregiver’s productivity loss.  While in Base -case B, at ¥12,000 (US$150)/¥16,000 
(US$200) per shot, the replacement will save money and gain more QALY or YOLS 
regardless of caregiver’s productivity loss.  
Sensitivity analyses on VEs performed on Base-case B show that the VE of 
PCV-13 against AOM (1 to <2 year) has the largest impact on the result, with its 
lower/upper value increasing/decreasing the ICER about ¥9,000,000 (US$11,250) per 
QALY. 
The probabilistic sensitivity analyses show that the probabilities of PCV-13 
programme to be under ¥5,000,000 (US$62,500) per QALY are 0.1% (Base-case A, 
care-giver’s productivity loss not included) to 99.9% (Base-case B, care-giver’s 
productivity loss included).  
In Base-case B, the ICERs in QALY of our base-case analyses, scenario analyses 
and sensitivity analyses are all less than a willingness-to-pay threshold suggested for 
healthcare intervention, i.e., ¥5,000,000 (US$62,500) per QALY gained [34], and are 
under WHO’s cost-effective criterion for intervention, i.e., less than 3 times of GDP per 
capita (≑¥11,000,000 or US$137,500 in Japan) [39].  Therefore, when we consider the 
“value for money”, the replacement of PCV-7 with PCV-13 vaccination programme 
would be a socially acceptable option in Japan from the viewpoint of health economics.   
On the other hand, in Base-case A, unless the cost of one PCV-13 shot is equal to or less 
than ¥11,000 (US$138), the ICERs would all be over ¥11,000,000 (US$137,500).  
Therefore the replacement is not considered a socially acceptable option in Japan.  
A recent study reported the cost -effectiveness ratio (CER) of Rotavirus 
vaccination programme in Japan, of which ratio was ¥9.8 million per QALY.[40]  This 
is larger than our CERs of PCV-7 or PCV-13, which is ¥6.4 million or ¥9.0 million per 
QALY, respectively.  Several studies from overseas reported on the cost-effectiveness 
of introducing PCV-13.  Among them, some compared PCV-7 and PCV-13 with 
no-programme from the societal perspective and found PCV-13 is more cost-effective 
than PCV-7 with or without considering net-indirect effect [6, 32].  By taking the 
cost-effective ratios (CERs) of PCV-7/PCV-13 vaccination programme and comparing 
them to that of no-programme, our study yields a result that is consistent with those 
previous studies.  On the other hand, some studies evaluated the transition of PCV-7 to 
PCV-13 [3-5, 41].  Conclusions drawn from the replacement of PCV-7 with PCV-13 
ranged from borderline cost -effective (England) [41] to cost-saving (USA, Germany, 
Greece, and The Netherlands) [3-5].  Although there are lots of differences between 
our study and theirs, we share the same determination in evaluating the replacement of 
PCV-7 to PCV-13, as it is highly relevant to countries where PCV-7 has been offered 
under the national immunisation programme. 
Our analysis is simple and straightforward based on the limited knowledge of 
epidemiology, and the assumption we made on efficacy or effectiveness of PCV-7 and 
PCV-13 may suggest an overestimation or underestimation of the results.  However, 
evidences adopted are the best available ones to date, and assumptions made are the 
most conservative under the current uncertainty.  The main limitations of our study are 
as follows:  First, clinical evidences which show the effectiveness of vaccination in 
reducing annual incidence rates of the diseases in our model are adopted from studies 
carried out in other countries, since no similar study has been done in Japan.  There 
should be differences in ethnicity as well as in the health system between those 
countries and Japan.  Second, annual incidence rate of hospitalised pneumonia used in 
this study is based on a study done in only one prefecture because of the unavailability 
of national surveillance data, and such data would have a bias.  Third, we did not 
include the benefits of vaccination in preventing antibiotic  resistance in our model.  
Including this benefit would bring more cost-effective results given that the serotypes 
identified as penicillin resistant and covered by PCV-7 is above 80% in Japan [8, 29].  
5. Conclusion 
Our study finds that if PCV-13 had additional protection against AOM compared 
to PCV-7 and cost per PCV-13 shot is 1.7 times less than that of PCV-7, a PCV-13 
vaccination programme offered to the birth cohort in Japan is likely to be a socially 
acceptable option compared to the current PCV-7 vaccination programme.  
Furthermore, if cost per PCV-13 shot is 1.2 times less than that of PCV-7, replacing 
PCV-7 with PCV-13 will save money and gain more QALYs.  However, if PCV-13 had 
no additional protection against AOM, the replacement can only be acceptable if cost 
per PCV-13 shot is 1.1 times less than of that of PCV-7.  Due caution is needed in 
transferring these findings from our Japanese model to other health system, even so, 
replacing PCV-7 with PCV-13 to protect the birth cohort could be economically 
acceptable in developed countries . 
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Table 1. Epidemiological data used on model 
 
Variable   Reference 
Vaccine uptake rate 76.1%     
  
12 
Population of birth cohort  entering  the model, unit:1000 Total Male Female 
  
15 
  1st year   1,004 515 489 
 
  
  2nd year  981 504 478 
 
  
  3rd year 954 489 464 
 
  
  4th year 926 475 451 
 
  
  5th year 900 462 438 
 
  
    Age groups 
     
    0 to <1 1 to <2 2 to <3 3 to <4 4 to <5   
Annual incidence rates per 100,000 population             
  Invasive pneumococcal disease cases: meningitis    7.46 3.83 1.11 0.94 0.27 20 
  Invasive pneumococcal disease cases: bacteraemia 15.2 45.4 12 5.8 4 20 
  Clinically diagnosed AOM episodes 103,100 113,881 67,160 52,589 40,371 21 
  All-causes hospitalised CAP 1,760 1,760 1,760 1,760 1,760 23 
Proportion of meningitis that results to hearing impairment; % 3.3  3.3  3.3  3.4  3.4  20,24 
Proportion of meningitis that results to neurological sequelae; % 15.7  15.7  15.7  15.6  15.6  20,24 
Proportion of clinically diagnosed AOM episodes  due to pneumococcus; % 34.1 34.1 34.1 34.1 34.1 22 
Case fatality rate; %             
  Bacteraemia 0.04 0.04 0.04 0.04 0.04 20 
  Meningitis 0.21 0.21 0.21 0.21 0.21 20 
  Hospitalised pneumonia 0.11 0.11 0.11 0.11 0.11 25,26 
Vaccine effectiveness (VE) of PCV-7*; %              
  In reducing vaccine serotype IPD 80.0 80.0 77.6 75.3 73.0 27 
  In reducing vaccine serotype AOM 54.0 54.0 572.4 50.8 49.3 27 
  In reducing hospitalised pneumonia 27.0 27.0 26.2 25.4 24.6 28 
Proportion of IPD episodes due to PCV-7 serotype; % 68.5 
    
7 
Proportion of IPD episodes due to PCV-13 serotype; % 80.9     7 
Proportion of hospitalized CAP episodes due to PCV-7 serotype; % 66.7     23 
Proportion of hospitalized CAP episodes due to PCV-13 serotype; % 81.0     23 
Proportion of AOM episodes due to PCV-7 serotype; % 68.2 68.2 68.2 48.5 48.5 29 
Proportion of AOM episodes due to PCV-13 serotype; % 86.0 86.0 86.0 77.9 77.9 29 
Life expectancy of neurological sequelae 53.9        10 
Life expectancy of Japanese population at age 5 74.9 male; 80.8 female  
  
10 
Utility weight   10 
  Healthy 1 
  
 
  
  Hearing impairment 0.9  
  Neurological sequelae 0.57  
  Curable bacteraemia 0.9921  
  Curable meningitis 0.9768  
  Curable pneumonia 0.994  
  AOM 0.995  
  Death 0  
*VEs of PCV-13 are assumed to be as immunogenic as PCV-7 for common serotypes and has comparable levels of antibody for serotypes unique to PCV-13.  
 
  
Table 2 Base-cases and scenarios 
Base-case A No net indirect effect. Not effective against serotypes unique to PCV-13 (1, 3, 5, 6A, 7F, 19A) 
Base-case B No net indirect effect. Effective against serotypes unique to PCV-13 (1, 3, 5, 6A, 7F, 19A) 
  
Scenario-1 Net indirect effect to non-vaccinated aged under 5.  The effect to IPD only.  No net indirect effect to aged over 5. 
Scenario-2 Net indirect effect to non-vaccinated aged under 5.  The effect to IPD, hospitalised pneumonia.  No net indirect effect to aged over 5. 
Scenario-3 Net indirect effect to non-vaccinated aged under 5.  The effect to IPD, AOM.  No net indirect effect to aged over 5. 
Scenario-4 Net indirect effect to non-vaccinated aged under 5.  The effect to IPD, hospitalised pneumonia, AOM.  No net indirect effect to aged over 5. 
 
Table 3 Costs 
Variable           Reference 
Cost per PCV-7 ¥10,000  
 
      10 
Cost per PCV-13  ¥13,000  
 
      34 
 
  Age groups           
Treatment cost: 0 to <1 1 to <2 2 to <3 3 to <4 4 to <5   
  Bacteraemia episode, survive ¥419,153 ¥419,153 ¥419,153 ¥392,802 ¥392,802 24 
  Bacteraemia episode, death ¥1,032,126 ¥1,032,126 ¥1,032,126 ¥1,010,205 ¥1,010,205 24 
  Meningitis episode, survive ¥852,642 ¥852,642 ¥852,642 ¥843,867 ¥843,867 24 
  Meningitis episode, death ¥1,470,421 ¥1,470,421 ¥1,479,196 ¥1,510,669 ¥1,510,669 24 
  Pneumonia episode ¥221,133 ¥221,133 ¥221,133 ¥164,916 ¥164,916 35 
  AOM episode ¥31,990 ¥35,313 ¥61,927 ¥43,659 ¥44,359 21 
  Hearing impairment (long term treatment )/year ¥79,422 ¥79,422 ¥79,422 ¥78,057 ¥78,057 21 
  Neurological sequelae (long term treatment)/year ¥420,464 ¥420,464 ¥420,464 ¥380,671 ¥380,671 21 
               
Variables related to care-giver's productivity loss Age groups           
  Frequency of outpatient visits/number of hospitalisation days 0 to <1 1 to <2 2 to <3 3 to <4 4 to <5   
  Bacteraemia episode  2.9 visits/11.5 days 2.8 visits/10.5 days 21 
  Meningitis episode  8.1 visits/22.7 days  7.8 visits/21.1days 21 
  Pneumonia episode  2.7 visits/6.8 days  2.8  visits/4.9 days 35 
  Hearing impairment 
8 hours per day until the child is admitted to special support education system 
21 
  Neurological sequelae  
21 
         Absent working hours per AOM episode (h) 33.6 27.7 50.3 43.1 39.4 
Average hourly wage of Japnaese women labourers  ¥1,328 
 
      36 
  US$1 = \80             
  
Table 4 Results of Base-case analyses 
 
  Base-case A:  PCV-13 with no additional VE to PCV-7 on AOM*   Base-case B:  PCV-13 with additional VE to PCV-7 on AOM 
  Cost  per child    Cost  per child  
  Vaccine cost 
Diseases   treatment 
costs 
Productivity loss 
(uptake vaccine) 
Productivity loss 
(disease treatment) 
  Vaccine cost 
Diseases   treatment 
costs 
Productivity loss 
(uptake vaccine) 
Productivity loss 
(disease treatment) 
No programme ¥0 ¥64,346 ¥0 ¥62,931   ¥0 ¥64,346 ¥0 ¥62,931 
PCV-7                                                             ¥28,725 ¥49,747 ¥4,414 ¥47,924   ¥28,725 ¥49,747 ¥4,414 ¥47,924 
PCV-13 ¥37,342 ¥48,975 ¥4,414 ¥47,479   ¥37,342 ¥41,507 ¥4,414 ¥38,646 
  Effect per child     Effect per child   
  QALY YOLS     QALY YOLS   
No progaramme 32.8087  32.8152      32.8087  32.8152    
PCV-7                                                            32.8109  32.8158      32.8109  32.8158    
PCV-13 32.8111  32.8160      32.8120  32.8160    
  Cost/QALY   Cost/QALY   Cost/YOLS Cost/YOLS   Cost/QALY   Cost/QALY   Cost/YOLS Cost/YOLS 
CER/ICER 
    Without     
productivity loss 
With       
productivity loss 
     Without    
productivity loss 
With          
productivity loss 
  
    Without     
productivity loss 
With       
productivity loss 
     Without    
productivity loss 
With          
productivity loss 
PCV-7 vs.  No programme                                                          ¥6,352,110 ¥1,588,575 ¥23,512,220 ¥5,880,083   ¥6,352,110  ¥1,588,575  ¥23,512,220  ¥5,880,083  
PCV-13 vs.  No programme                                                                      ¥9,034,940 ¥4,495,903 ¥29,476,620 ¥14,667,948   ¥4,368,278   cost less, gain more ¥19,457,218  cost less, gain more 
PCV-13 vs. PCV-7                                                                               ¥37,722,901 ¥35,584,455  ¥54,261,241 ¥51,185,265    ¥343,830  cost less, gain more ¥2,606,959 cost less, gain more 
*Based on the package insert of PrevenarⓇ 
   
Table 5 Results of Scenario analyses 
  PCV-13 vs. PCV7  
  Cost/QALY Cost/QALY 
  
Without productivity 
loss 
with      
productivity loss 
Base-case A ¥37,722,901  ¥35,584,455  
Scenario-1 ¥33,661,992  ¥31,387,802  
Scenario-2 ¥27,824,591  ¥25,683,001  
Scenario-3 ¥31,387,702  ¥31,387,802  
Scenario-4 ¥25,682,885  ¥25,683,001  
Base-case B ¥343,830  cost less, gain more 
Scenario-1 ¥308,676  cost less, gain more 
Scenario-2 ¥115,860  cost less, gain more 
Scenario-3 cost less, gain more cost less, gain more 
Scenario-4 cost less, gain more cost less, gain more 
 
  
 
Fig. 1 Markov model 
1st to 5th year birth cohort are from Population estimates of Japan. 
“Healthy” means being without the diseases defined by the model.  The “++entry++”indicates new birth cohort which falls into programmes 
during the 2nd to 5th year after the start of the vaccination programme. No program is shown as reference. 
  
Fig. 2 The effect on ICERs by changing cost of PCV-13 
The grey area shows cost saving, i.e., cost less and gain more  
   
  
Fig.3 Sensitivity analyses performed on vaccine effectiveness 
  
Fig. 4. Cost-effectiveness acceptability curves (CEACs) for Base-cases with/without care-giver’s productivity loss 
CEAC is a commonly used visual aid for communicating the results of probabilistic sensitivity analysis in cost-effectiveness models, which 
presents relative cost-effectiveness as a function of the threshold ICER.  The graphed value of any comparator at a particular willingness-to-pay 
represents the probability that it is cost-effective, based on the uncertainties included in the simulation. 
